--- title: "Herbalife (HLF) On Raised 2026 Guidance And CFO Change Looks Undervalued" type: "News" locale: "en" url: "https://longbridge.com/en/news/296128007.md" description: "Herbalife (HLF) raised its 2026 net sales guidance and announced a CFO transition, prompting analysis of its valuation. Despite short-term gains, the stock remains significantly below its five-year high. Analysts estimate a fair value of $17.00, suggesting the stock is undervalued by approximately 27.5% compared to its recent close of $12.33. This view relies on expected earnings growth, margin improvements, and a leaner valuation multiple, though risks include regulatory scrutiny of its multi-level marketing model and flat volumes in certain regions." datetime: "2026-08-17T15:53:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296128007.md) - [en](https://longbridge.com/en/news/296128007.md) - [zh-HK](https://longbridge.com/zh-HK/news/296128007.md) generator: "portal-rs" --- # Herbalife (HLF) On Raised 2026 Guidance And CFO Change Looks Undervalued Herbalife (HLF) is back in focus after revising its full year 2026 net sales guidance upward and announcing a planned CFO transition. These developments give investors fresh information on both outlook and leadership. See our latest analysis for Herbalife. Herbalife’s latest guidance and CFO transition sit against a mixed price picture, with the 7-day share price return of 7.03% and 1-year total shareholder return of 34.46% contrasting with a decline of 75.16% over five years on a total shareholder return basis. If Herbalife’s recent guidance change has you rethinking where growth stories might emerge next, it could be a good moment to scan 21 top founder-led companies With Herbalife shares rebounding in the short term but still far below their 5 year level, the key issue now is whether the current valuation still compensates you for the earnings swings and the leadership change that lies ahead. ## Most Popular Narrative: 27.5% Undervalued Compared with Herbalife's last close at $12.33, the most followed narrative sets fair value at $17.00, which frames the current debate around upside potential and execution risk. > *The company continues to experience flat to declining volumes in several regions, with only modest improvements in constant currency net sales, indicating that the addressable market for Herbalife's traditional model may be reaching maturity and that top-line revenue growth could remain pressured.* *Read the complete narrative.* Want to understand why this maturity concern still supports a higher value for Herbalife? The narrative leans on a specific mix of earnings growth, margin reset and a leaner future valuation multiple that might surprise you. **Result: Fair Value of $17.00 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, Herbalife still faces regulatory scrutiny of its multi level marketing model and evolving consumer preferences around supplements, which could challenge the earnings and margin narrative. Find out about the key risks to this Herbalife narrative. ## Next Steps If the mixed tone around Herbalife leaves you unsure, now is a good time to review both sides of the story yourself. To consider the key risks and potential upsides in one place, start with the 3 key rewards and 5 important warning signs ## Looking for more investment ideas beyond Herbalife? If Herbalife has sharpened your focus on opportunities, do not stop here. Use the Simply Wall St Screener to spot other stocks that fit your style. - Target potential mispricings by scanning companies that combine quality with value through the 52 high quality undervalued stocks. - Prioritize resilience by checking stocks with stronger financial footing and efficient balance sheets in the solid balance sheet and fundamentals stocks screener (50 results). - Hunt for lesser known opportunities with solid fundamentals using the screener containing 19 high quality undiscovered gems. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### Valuation is complex, but we're here to simplify it. Discover if Herbalife might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [HLF.US](https://longbridge.com/en/quote/HLF.US.md) ## Related News & Research - [Herbalife to Present and Host 1x1 Investor Meetings at Midwest IDEAS Investor Conference on August 26 | HLF Stock News](https://longbridge.com/en/news/295787262.md) - [Herbalife Q2 adjusted EPS misses estimates on FX headwinds](https://longbridge.com/en/news/295009232.md) - [Is it Time to Begin Accumulating Natural Gas?](https://longbridge.com/en/news/295953555.md) - [Should you buy Micron Technology stock below $920 per share? Wall Street thinks it's heading to $1,500.](https://longbridge.com/en/news/295997501.md) - [Southern Copper (NYSE:SCCO) Shares Up 8.3% - Still a Buy?](https://longbridge.com/en/news/296638179.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**